Palatin Technologies, Inc. (LON:0KF3)

Market Cap	24.06M +16.1%
Revenue (ttm)	6.66M +2,461.0%
Net Income	-7.15M
EPS	-5.89
Shares Out	1.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	10
Open	19.54
Previous Close	18.78
Day's Range	18.50 - 20.40
52-Week Range	3.67 - 27.71
Beta	-0.09
RSI	44.86
Earnings Date	May 14, 2026

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1986
• Employees: 29
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KF3

Financial Performance

Financial numbers in USD